Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
Jefferies Global Healthcare Conference in London,
Third quarter 2026 revenue growth of 36% driven by strong performance in Oncology and Screening
Raises 2026 revenue guidance to $1.36 to $1.37 billion, representing growth of 38% to 40%
Guardant Health, Inc.
All 23 claims of the ‘631 patent exclusively licensed to TwinStrand remain intact following unappealable decision on reexamination initiated by Guardant Health
Decision follows second USPTO Patent Trial and Appeal
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is former CEO of Dexcom, Inc. and current Executive Chairman
Shield blood test for colorectal cancer (CRC) recognized for impact in increasing screening participation for CRC and closing today’s screening gaps
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology
Two million more screening-eligible Pennsylvanians will now have access to the Shield blood test for colorectal cancer (CRC) with no cost-sharingGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company,
Research reinforces the significance of genomic and epigenomic profiling approaches to characterize tumor types, identify biomarkers, and support risk stratification
Presentations reflect Guardant’s strong
Following Federal Circuit remand, the PTAB again rules in favor of the University of Washington and TwinStrand on all 30 claims of the ’127 patent challenged by Guardant Health
TwinStrand Biosciences (TwinStrand),
Modeling study provides strong data on real-world follow-up colonoscopy adherence and CRC deaths averted for blood-based testing vs stool-based testing
New data demonstrates notable screening adherence rate of 99%
Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographies
This latest approval marks Guardant’s 31st CDx approval
Guardant Health, Inc.
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management
First published prospective, multicenter study of Guardant Reveal in resected melanoma demonstrates 81% sensitivity for distant recurrence and 100% post-treatment specificity
Molecular residual disease detection
Second largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholders
Milestone marks rapid adoption by
Research highlights the significance of genomic and epigenomic profiling approaches to characterize lung tumors, identify biomarkers, and support risk stratification
Real-world studies examine the complementary
Earning the highest five-star recognition alongside only 12 other companies in the biotechnology category
Recognition underscores Guardant’s leadership in precision oncology including patient growth and years of
